10x Genomics, Inc. (TXG): Growth-Adjusted P/E Ratio
10x Genomics, Inc. (TXG) is adapting its model by prioritizing reagent sales revenue over instrument expansion. The P/E ratio, adjusted for EPS growth, clearly captures the market valuation phases, with the value holding at 0.00. Growth relies on patent protection and laboratory budgets, while the low cyclicality of consumables sales provides resilience against macroeconomic shocks.
Analytical breakdowns for 10x Genomics, Inc. (TXG)
- current quotes and average value forecast:
- stock exchange capitalization data:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Total Debt to Capital Coefficient 10x Genomics, Inc.|TXG - Long-Term Debt to Capital|Short-Term Debt to Equity Ratio 10xgenomics.com|TXG - Company Debts|Debts to Net Assets 10x Genomics Corp|TXG - Company Long-Term Liabilities|Company Short-Term Loans and Borrowings 10x Genomics|Interim Coverage Ratio 10xgenomics.com
- earnings and multiples data:
TXG - Company Net Income|Net Profit Forecast 10x Genomics, Inc.|TXG - P/E Multiple|Projected Price to Earnings 10x|TXG - Price/Earnings to Growth Multiple|Total Company Value to Operating Income Before Depreciation Ratio 10x Genomics Corp|TXG - Operating profit before deduction of amortization|Earnings per share for the last four quarters 10x Genomics|TXG - Net earnings per share for the last 12 months|Year-over-year earnings per share growth for the last 12 months 10xgenomics.com|TXG - Earnings growth in current year|Net earnings per one share growth forecast for next year 10x Genomics, Inc.
Fundamental company analysis:TXG, 10x Genomics Inc
To select assets with a high margin of safety, the PEG ratio is used, which correlates the P/E multiple with earnings growth rates, identifying undervaluation when the value is below one. The current 0.00 metric reflects the market value of 10x Genomics, Inc. (TXG) relative to the expansion of the Xenium platform and the recovery of academic budgets, allowing for an assessment of risk asymmetry through the growth stock undervaluation coefficient.
Who 10x Genomics, Inc. competes with
TEM - Price to Earnings Adjusted for Growth Rate|Price/Earnings to Growth Ratio Qiagen Group QGEN|IONS: Growth-Adjusted P/E Ratio|RGEN - Price/Earnings to Growth Ratio|Price to Earnings Adjusted for Growth Rate aviditybiosciences.com|CRISPR Therapeutics (CRSP) - Price/Earnings to Growth Ratio|Price/Earnings to Growth Multiple GeneDx Holdings|RARE (Ultragenyx Pharma) - PEG Multiple|Beam Tx (BEAM) - Growth-Adjusted Market Cap to Net Income|PEG Multiple SRPT|Price/Earnings to Growth Multiple twistbioscience.com TWST|Price/Earnings to Growth Ratio Intellia Therapeutics, Inc. NTLA|Growth-Adjusted Market Cap to Net Income Stoke Therapeutics Inc (STOK)|BLFS: Price/Earnings to Growth Multiple|Growth-Adjusted Payback Ratio WVE (Wave Pharma)|MAZE: PEG Multiple|SION - Growth-Adjusted Market Cap to Net Income|Price/Earnings to Growth Ratio Prime Medicine|Growth-Adjusted P/E Ratio TSHA (Taysha Gene Therapies Inc)|PEG Multiple QURE|Price/Earnings to Growth Multiple MeiraGTx Corp MGTX|REGENXBIO Inc. - Price/Earnings to Growth Multiple|Growth-Adjusted Market Cap to Net Income solidbio.com (SLDB)|OCGN: Price/Earnings to Growth Multiple|Pacific Biosciences of California, Inc. - Company Value to Earnings Growth Ratio|BNTC (Benitec) - Price/Earnings to Growth Multiple|Growth-Adjusted P/E Ratio DSGN|RCKT (Rocket Pharmaceuticals) - PEG Multiple|FDMT - Price to Net Income Growth Ratio|PEG Multiple LXEO|korrobio.com - Growth-Adjusted P/E Ratio|Price/Earnings to Growth Ratio Editas EDIT|SLN: Growth-Adjusted P/E Ratio|ProQR Therapeutics NV - PEG Multiple|CDXS - PEG Multiple|SGMO: PEG Multiple|NAUT: Company Value to Earnings Growth Ratio|Price/Earnings to Growth Multiple MGX|Growth-Adjusted P/E Ratio DTIL (Precision BioSciences Inc.)|Price/Earnings to Growth Multiple GBIO (Generation Bio Co.)|BOLD (boundlessbio.com) - Growth-Adjusted Payback Ratio|PEG Multiple XCUR (Exicure)|Price to Net Income Growth Ratio Imunon Inc|RXi Pharmaceuticals - PEG Multiple|Price to Earnings Adjusted for Growth Rate Mustang Bio, Inc.|transcodetherapeutics.com (RNAZ) - Price/Earnings to Growth Ratio|Growth-Adjusted P/E Ratio BNGO|Price/Earnings to Growth Ratio Applied DNA Sciences, Inc.|Price to Earnings Adjusted for Growth Rate bluebird bio Inc. BLUE|Price/Earnings to Growth Ratio ImmunoPrecise Antibodies (IPA)|Price/Earnings to Growth Multiple Omega Therapeutics Corp OMGA|PEG Multiple OMIC (Singular Genomics Systems)|Growth-Adjusted Market Cap to Net Income regulusrx.com (RGLS)|Syros Pharmaceuticals, Inc. - PEG Multiple|Telesis Bio Inc. (TBIO) - Price/Earnings to Growth Multiple|TRACON (TCON) - Price/Earnings to Growth Ratio|UBX - Growth-Adjusted Market Cap to Net Income
